공시 • Mar 13
Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026 Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 66, jeyakgongdan 1-gil, hyangnam-eu, gyeonggi-do, hwaseong South Korea Upcoming Dividend • Dec 22
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%). Reported Earnings • Nov 19
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: ₩48.9b (flat on 3Q 2024). Net income: ₩2.61b (up 33% from 3Q 2024). Profit margin: 5.3% (up from 4.0% in 3Q 2024). Declared Dividend • Nov 08
Dividend of ₩100.00 announced Dividend of ₩100.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.6%, which is higher than the industry average of 1.1%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. 공시 • Nov 07
Daehan Nupharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026 Daehan Nupharm Co.,Ltd. announced Annual dividend of KRW 100.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. New Risk • Aug 15
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 8.0% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.0% operating cash flow to total debt). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₩101.9b market cap, or US$73.5m). 공시 • Mar 05
Daehan New Pharm Co., Ltd., Annual General Meeting, Mar 20, 2025 Daehan New Pharm Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: seminar room, 66, jeyakgongdan 1-gil, hyangnam-eup, gyeonggi-do, hwaseong South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 15 April 2025. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%). Upcoming Dividend • Dec 20
Upcoming dividend of ₩100.00 per share at 1.1% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (1.1%). Upcoming Dividend • Dec 21
Inaugural dividend of ₩80.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 13 April 2023. This is the first dividend for Daehan New Pharm since going public. The average dividend yield among industry peers is 1.0%. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩8,300, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 26% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₩10,900, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 13% over the past three years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Is New 90 Day High Low • Feb 22
New 90-day low: ₩11,650 The company is down 11% from its price of ₩13,100 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Is New 90 Day High Low • Feb 04
New 90-day low: ₩11,700 The company is down 2.0% from its price of ₩11,950 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Reported Earnings • Nov 16
Third quarter 2020 earnings released: ₩82.00 loss per share The company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ₩39.5b (up 23% from 3Q 2019). Net loss: ₩1.16b (down 137% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. 
